---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-24-000034"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:39:07.384725+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio Q1 net loss $15.5M ($0.40/sh); cash $130M; VTP-1000 IND cleared for celiac trial

## Summary
- Net loss attributable to shareholders of $15.5M vs $18.2M in Q1 2023; revenue nil (vs $0.5M).
- Cash, cash equivalents and restricted cash of $130.0M as of March 31, 2024; cash runway into Q4 2025.
- R&D expenses $11.1M (up from $9.8M), G&A $6.0M (down from $12.1M).
- FDA IND clearance received for VTP-1000 Phase 1 trial in celiac disease; first patient dosing expected Q3 2024.
- Appointed Dr. Leon Hooftman as CMO, effective June 3, 2024.

## SEC filing metadata
- accession: 0001828185-24-000034
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000034/0001828185-24-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000034/brns-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-24-000034
- JSON: https://secwatch.observer/filing/0001828185-24-000034.json
- Plain text: https://secwatch.observer/filing/0001828185-24-000034.txt

## Key facts
- Earnings Releases
  Barinthus Biotherapeutics plc. reported financial results for first quarter of 2024.
  - Period: first quarter of 2024
  - Result: reported results
  source text: On May 13, 2024, Barinthus Biotherapeutics plc (the “Company”) announced its financial results for the first quarter of 2024 and provided an overview of the Company’s progress. The full text of the press release issued in connection with the update is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000034/0001828185-24-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.